Evaluation of the antiprion activity of 6-aminophenanthridines and related heterocycles

European Journal of Medicinal Chemistry

Volumn 82, Issue , 2014, Pages 363-371

  Nguyen, Phuhai ^a   Oumata, Nassima ^b   Soubigou, Flavie ^a   Evrard, Justine ^a   Desban, Nathalie ^c   Lemoine, Pascale ^d   Bouaziz, Serge ^d   Blondel, Marc ^a   Voisset, Cécile ^a  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^b Centre National de la Recherche Scientifique   (France)

^c CNRS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Neurodegenerative diseases; Phenanthridine; Prions; Protein misfolding

Indexed keywords

6 (2,4 DIMETHOXYBENZYLAMINO)PHENANTHRIDINE; 6 AMINO 2 METHYLPHENANTHRIDINE; 6 AMINO 2 TRIFLUOROMETHOXYPHENANTHRIDINE; 6 AMINO 2,4 DIMETHOXYPHENANTHRIDINE; 6 AMINO 7 FLUOROPHENANTHRIDINE; 6 AMINO 7 NITROPHENANTHRIDINE; 6 AMINO 8 AZIDOPHENANTHRIDINE; 6 AMINO 8 FLUOROPHENANTHRIDINE; 6 AMINO 8 NITROPHENANTHRIDINE; 6 AMINO 8 TRIFLUOROMETHYLPHENANTHRIDINE; 6 AMINO 9 FLUOROPHENANTHRIDINE; 6 AMINO 9 METHYLPHENANTHRIDINE; 6 AMINO 9 N METHYLSULFONAMIDOPHENANTHRIDINE; 6 AMINO 9 NITROPHENANTHRIDINE; 6 AMINOPHENANTHRIDINE DERIVATIVE; 6,7 DIAMINOPHENANTHRIDINE; 6,8 DIAMINOPHENANTHRIDINE; 7,10 DIHYDROPHENANTHRIDIN 6 AMINE; 7,8,9,10 TETRAHYDROPHENANTHRIDIN 6 AMINE HYDROCHLORIDE; 8 AMINO 6 PHTALIMIDOPHENANTHRIDINE; 8 AZIDO 6 AMINOPHENANTHRIDINE; 8 AZIDO 6 PHTALIMIDOPHENANTHRIDINE; ANTIVIRUS AGENT; BENZO[C 1,5]NAPHTYRIDIN 6 YLAMINE; BENZO[C 1,6]NAPHTYRIDIN 6 YLAMINE; BENZO[C 2,6]NAPHTYRIDIN 5 YLAMINE; GUANIDINE; HETEROCYCLIC COMPOUND; PHENANTHRIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; 6-AMINOPHENANTHRIDINE; PRION;

ANTIVIRAL ACTIVITY; ARTICLE; CELL ASSAY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG SCREENING; EX VIVO STUDY; IC 50; MAMMAL; NONHUMAN; PRION; STRUCTURE ACTIVITY RELATION; SUZUKI REACTION; YEAST; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; MOUSE; SACCHAROMYCES CEREVISIAE; SYNTHESIS; TRANSGENIC MOUSE;

ANIMALS; HETEROCYCLIC COMPOUNDS; MICE; MICE, TRANSGENIC; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHENANTHRIDINES; PRIONS; SACCHAROMYCES CEREVISIAE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84902315605     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.05.083     Document Type: Article

References (26)

1. S.K. Kaufman, and M.I. Diamond Prion-like propagation of protein aggregation and related therapeutic strategies Neurotherapeutics 10 2013 371 382
2. Y.O. Kamatari, Y. Hayano, K. Yamaguchi, J. Hosokawa-Muto, and K. Kuwata Characterizing antiprion compounds based on their binding properties to prion proteins: implications as medical chaperones Protein Sci. 22 2013 22 34
3. A. Gallardo-Godoy, J. Gever, K.L. Fife, B.M. Silber, and S.B. Prusiner et al. 2-Aminothiazoles as therapeutic leads for prion diseases J. Med. Chem. 54 2011 1010 1021
4. M.J. Thompson, J.C. Louth, S. Ferrara, F.J. Sorrell, and B.J. Irving et al. Structure-activity relationship refinement and further assessment of indole-3-glyoxylamides as a lead series against prion disease ChemMedChem 6 2011 115 130
5. M.J. Thompson, J.C. Louth, S.M. Little, B. Chen, and I. Coldham 2,4-diarylthiazole antiprion compounds as a novel structural class of antimalarial leads Bioorg. Med. Chem. Lett. 21 2011 3644 3647
6. M.L. Bolognesi, H.N. Ai Tran, M. Staderini, A. Monaco, and A. Lopez-Cobenas et al. Discovery of a class of diketopiperazines as antiprion compounds ChemMedChem 5 2010 1324 1334
7. V. Villa, M. Tonelli, S. Thellung, A. Corsaro, and B. Tasso et al. Efficacy of novel acridine derivatives in the inhibition of hPrP90-231 prion protein fragment toxicity Neurotox. Res. 19 2011 556 574
8. E. Chung, F. Prelli, S. Dealler, W.S. Lee, and Y.T. Chang et al. Styryl-based and tricyclic compounds as potential anti-prion agents PLoS One 6 2011 e24844
9. G. Poli, E. Corda, P.A. Martino, P. Dall'ara, and S.R. Bareggi et al. Therapeutic activity of inhibition of the soluble epoxide hydrolase in a mouse model of scrapie Life Sci. 92 2013 1145 1150
10. Y. Roettger, Y. Du, M. Bacher, I. Zerr, and R. Dodel et al. Immunotherapy in prion disease Nat. Rev. Neurol. 9 2013 98 105
11. C. Mangels, A.O. Frank, J. Ziegler, R. Klingenstein, and K. Schweimer et al. Binding of TCA to the prion protein: mechanism, implication for therapy, and application as probe for complex formation of bio-macromolecules J. Biomol. Struct. Dyn. 27 2009 163 170
12. S. Bach, N. Talarek, T. Andrieu, J.M. Vierfond, and Y. Mettey et al. Isolation of drugs active against mammalian prions using a yeast-based screening assay Nat. Biotechnol. 21 2003 1075 1081 (Pubitemid 37064738)
13. D. Tribouillard-Tanvier, V. Beringue, N. Desban, F. Gug, and S. Bach et al. Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions PLoS ONE 3 2008 e1981
14. N. Oumata, P.H. Nguyen, V. Beringue, F. Soubigou, and Y. Pang et al. The toll-like receptor agonist imiquimod is active against prions PLoS One 8 2013 e72112
15. F. Gug, N. Oumata, D. Tribouillard-Tanvier, C. Voisset, and N. Desban et al. Synthesis of conjugates of 6-aminophenanthridine and guanabenz, two structurally unrelated prion inhibitors, for the determination of their cellular targets by affinity chromatography Bioconjug. Chem. 21 2010 279 288
16. D. Tribouillard-Tanvier, S. Dos Reis, F. Gug, C. Voisset, and V. Beringue et al. Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs PLoS ONE 3 2008 e2174
17. S. Bach, D. Tribouillard, N. Talarek, N. Desban, and F. Gug et al. A yeast-based assay to isolate drugs active against mammalian prions Methods 39 2006 72 77
18. D. Tribouillard, S. Bach, F. Gug, N. Desban, and V. Beringue et al. Using budding yeast to screen for anti-prion drugs Biotechnol. J. 1 2006 58 67
19. J.L. Vilotte, S. Soulier, R. Essalmani, M.G. Stinnakre, and D. Vaiman et al. Markedly increased susceptibility to natural sheep scrapie of transgenic mice expressing ovine prp J. Virol. 75 2001 5977 5984 (Pubitemid 32553128)
20. F. Archer, C. Bachelin, O. Andreoletti, N. Besnard, and G. Perrot et al. Cultured peripheral neuroglial cells are highly permissive to sheep prion infection J. Virol. 78 2004 482 490 (Pubitemid 37549758)
21. P. Brundin, R. Melki, and R. Kopito Prion-like transmission of protein aggregates in neurodegenerative diseases Nat. Rev. Mol. Cell. Biol. 11 2010 301 307
22. B. Frost, and M.I. Diamond Prion-like mechanisms in neurodegenerative diseases Nat. Rev. Neurosci. 11 2010 155 159
23. M. Goedert, F. Clavaguera, and M. Tolnay The propagation of prion-like protein inclusions in neurodegenerative diseases Trends Neurosci. 33 2010 317 325
24. N. Barbezier, A. Chartier, Y. Bidet, A. Buttstedt, and C. Voisset et al. Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy EMBO Mol. Med. 3 2011 35 49
25. A. Altomare, G. Cascarano, C. Giacovazzo, A. Guagliardi, M.C. Burla, G. Polidori, and M. Camalli SIR92-a program for automatic solution of crystal structures by direct methods J. Appl. Crystallogr. 27 1994 435
26. G. Sheldrick A short history of SHELX Acta Crystallogr. Sect. A 64 2008 112 122